Prevalence and impact of founder mutations in hereditary breast cancer in Latin America

Genetics and Molecular Biology

Volumn 37, Issue 1 SUPPL. 1, 2014, Pages 234-240

  Ashton Prolla, Patricia ^a,b   Vargas, Fernando Regla ^c,d  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

BRCA1; BRCA2; Breast cancer genes; Cancer predisposition; TP53

Indexed keywords

BRCA2 PROTEIN; PROTEIN P53;

ARTICLE; BRAZIL; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CHILE; COLOMBIA; COSTA RICA; FAMILIAL CANCER; GENE MUTATION; GERMLINE MUTATION; HUMAN; MEXICO; PHENOTYPE; PREVALENCE; SOUTH AND CENTRAL AMERICA; TUMOR SUPPRESSOR GENE; VENEZUELA;

EID: 84901670506     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572014000200009     Document Type: Article

References (54)

1. Achatz MIW, Olivier M, Calvez FL, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giuliani R, Palmero EI, Vargas FR, et al. (2007) The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndrome in Brazilian families. Cancer Lett 245:96-102.
2. Assumpção JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, et al. (2008) Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 8:e357.
3. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB and Varley JM (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621-4628.
4. Campos B, Díez O, Alvarez C, Palma L, Domènech M, Balmaña J, Sanz J, Ramírez A, Alonso C, Carvallo P, et al. (2004) Haplotype of the BRCA2 6857delAA mutation in 4 families with breast/ovarian cancer. Med Clin (Barc) 123:543-545.
5. Costa ECCB, Vargas FR, Moreira AS, Lourenço JJ, Caleffi M, Ashton-Prolla P and Martins Moreira MA (2008) Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovarian cancer syndrome. Cancer Genet Cytogenet 51:588-597.
6. Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, et al. (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932-1937.
7. Custódio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, Grisa L, Parise IZ, Pianovski MA, Fiori CM, et al. (2013) Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol 31:2619-2626.
8. Delgado L, Fernández G, González A, Bressac-de Paillerets B, Gualco G, Bombled J, Cataldi S, Sabini G, Roca R and Musé IM (2002) Hereditary breast cancer associated with a germline BRCA2 mutation in identical female twins with similar disease expression. Cancer Genet Cytogenet 133:24-28.
9. Dufloth RM, Carvalho S, Heinrich JK, Shinzato JY, dos Santos CC, Zeferino LC and Schmitt F (2005) Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med J 123:192-197.
10. Ewald IP, Izetti P, Vargas FR, Moreira MA, Moreira AS, Moreira-Filho CA, Cunha DR, Hamaguchi S, Camey AS, Schmidt A, et al. (2011) Prevalence of the BRCA1 founder mutation c.5266dup in Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hered Cancer Clin Pract 9:12.
11. Fackenthal JD and Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937-948.
12. Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Clolucci G, Bazan V and Russo A (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18(Suppl 6):93-98.
13. Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, et al. (2006) Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Breast Cancer Res Treat 95:81-87.
14. García-Jiménez L, Gutiérrez-Espeleta G and Narod SA (2012) Descriptive epidemiology and molecular genetics of hereditary breast cancer in Costa Rica. Rev Biol Trop 60:1663-1668.
15. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Plache G, LeCalvez-Kelm F, Brugières L, Vargas FR, Brentani RR, Ashton-Prolla P, et al. (2010) Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: Evidence for a founder effect. Hum Mutat 31:143-150.
16. Giacomazzi J, Toledo de Bueno Osorio CA, Koehler-Santos P, Graudenz MS, Martel-Planche G, Achatz MI, Soares FA, Goldim JR, Caleffi M, Hainaut P, et al. (2011) Contribution of TP53 p.R337H mutation to breast cancer incidence in Brazil. Cancer Res 15(Suppl 3):P1-09-07.
17. Giacomazzi J, Koehler-Santos P, Palmero EI, Graudenz MS, Rivero LF, Lima E, Putten AC, Hainaut P, Camey SA, et al. (2013) A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil. Virchows Arch 463:17-22.
18. Gomes MC, Costa MM, Borojevic R, Monteiro NA, Vieira R, Koiman S, Koifman RJ, Li S, Royer R, Zhang S, et al. (2007) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103:349-353.
19. Gutiérrez-Espeleta GA, Llacuachaqui M, García-Jiménez L, Aguilar Herrera M, Loaiciga Vega K, Ortiz A, Royer R, Li S and Narod SA (2012) BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica. Clin Genet 82:484-488.
20. Hamel N, Feng B-J, Foretova L, Stoppa-Lyonet D, Narod SA, Imyanitov E, Sininilkova A, Tihomirova L, Lubinski J, Gronwald J, et al. (2011) On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 19:300-306.
21. Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N, Zink M, Allolio B, Hahner S, et al. (2012) TP53 germline mutations in adult patients with adreno-cortical carcinoma. J Clin Endocrinol Metab 97:E476-485.
22. Infante M, Durán M, Esteban-Cardeñosa E, Miner C and Velasco E (2006) High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain). J Hum Genet 51:611-617.
23. Jara L, Ampuero S, Seccia L, Bustamante M, Blanco R, Santibañez E, Reyes JM and Ojeda JM (2002a) Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer. Rev Med Chil 130:1113-1123.
24. Jara L, Ampuero S, Seccia L, Bustamante M, Blanco R and Ojeda JM (2002b) Analysis of 5382insC (BRCA1) and 6174delT (BRCA2) mutations in 382 healthy Chilean women with a family history of breast cancer. Biol Res 35:85-93.
25. Jara L, Ampuero S, Santibáñez E, Seccia L, Rodriguez J, Bustamante M, Lay-Son G, Ojeda JM, Reyes JM and Blanco R (2004) Molecular analysis of the eighteen most frequent mutations in the BRCA1 gene in 63 Chilean breast cancer families. Biol Res 37:469-481.
26. Jara L, Ampuero S, Santibáñez E, Seccia L, Rodriguez J, Bustamante M, Martinez M, Catenaccio A, Lay-Son G, Blanco R, et al. (2006) BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet 166:36-45.
27. Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, Evans DG and Early Onset Breast Cancer Study Group (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361:1101-1102.
28. Lara K, Consigliere N, Pérez J, and Porco A (2012) BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res 45:117-130.
29. Lindor NM, McMaster ML and Lindor CJ (2008) Concise Handbook of Familial Cancer Susceptibility Syndromes Second Edition. J Natl Cancer Inst Monogr 38:1-93
30. Lourenço JJ, Vargas FR, Bines J, Santos EM, Lasmar CAP, Costa CH, Teixeira EM, Maia MCM, Coura F, Silva CHD, et al. (2004) BRCA1 mutations in Brazilian patients. Genet Mol Biol 27:500-504.
31. Machado PM, Brandão RD, Cavaco BM, Eugenio J, Bento S, Nave M, Rodriguez P, Fernandez A and Vaz F (2007) Screening for a large BRCA2 rearrangement in high-risk breast-ovarian cancer families: Evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027-2034.
32. Malkin D, Li FP, Strong LC, Fraumeni Jr JF, Nelson CE, Kim DH, Hassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238.
33. Moreira MA, Bobrovnitchaia IG, Lima MA, Santos AC, Ramos JP, Souza KR, Peixoto A, Teixeira MR and Vargas FR (2012) Portuguese c.156_157insAlu BRCA2 founder mutation: Gastrointestinal and tongue neoplasias may be part of the phenotype. Fam Cancer 11:657-660.
34. Narod S (2012) The tip of the iceberg. A countercurrent series. Curr Oncol 19:3.
35. Olivier M, Hollstein M and Hainaut P (2010) TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2:a001008.
36. Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, et al. (2008) Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 261:21-25.
37. Peixoto A, Santos C, Rocha P, Pinto P, Bizarro S and Teixeira MR (2009) Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu. Breast Cancer Res Treat 117:215-217.
38. Peixoto A, Santos C, Pinheiro M, Pinto M, Soares MJ, Rocha P, Gusmão L, Amorim A, van der Hout A, Gerdes AM, et al. (2011) International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat 127:671-679.
39. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, and Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629.
40. Pinto EM, Billerbeck AE, Villares MC, Domenice S, Mendonça BB and Latronico AC (2004) Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq Bras Endocrinol Metabol 48:647-650.
41. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, et al. (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 98:9330-9335.
42. Rodríguez AO, Llacuachaqui M, Pardo GG, Rover R, Larson G, Weitzel JN and Narod SA (2012) BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol 124:236-243.
43. Sanabria MC, Muñioz G and Vargas CI (2009) Mutations in the BRCA1 gene (185delAG and 5382insC) are not present in any of the 30 breast cancer patients analyzed from eastern Colombia. Biomedica 29:61-72.
44. Sanchez A, Faundez P and Carvallo P (2011) Genomic rearrangements of the BRCA1 gene in Chilean breast cancer families: An MLPA analysis. Breast Cancer Res Treat 128:845-853.
45. Salazar R, Cruz-Hernandez JJ, Sanchez-Valdivieso E, Rodriguez CA, Gomez-Bernal A, Barco E, Fonseca E, Portugal T and Gonzalez-Sarmiento R (2006) BRCA 1-2 mutations in breast cancer: Identification of nine new variants of BRCA 1-2 genes in a population from Western Spain. Cancer Lett 233:172-177.
46. Seidinger AL, Mastellaro MJ, Paschoal Fortes F, Godoy-Assumpção J, Aparecida Cardinalli I, Aparecida Ganazza M, Correia Ribeiro R, Brandalise SR, dos Santos Aguiar S and Yunes JA (2011) Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil. Cancer 117:2228-2235.
47. Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa L, Briceno I and Hamann U (2007) High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 103:225-232.
48. Vaca-Paniagua F, Alvarez-Gomez RM, Fragoso-Ontiveros V, Vidal-Millan S, Herrera LA, Cantu D, Bargallo-Rocha E, Mohar A, Lopez-Camarillo C and Perez-Plasencia C (2012) Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer. PLoS One 7:e37432.
49. Vidal-Millán S, Taja-Chayeb L, Gutiérrez-Hernández O, Ramirez Ugalde MT, Robles-Vidal C, Bargallo-Rocha E, Mohar-Betancourt A and Dueñas-Gonzalez A (2009) Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. Eur J Gynaecol Oncol 30:527-530.
50. Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, Mcguire C and Neuhausen S (2005) Prevalence of BRCA mutations and founder effect in high-risk hispanic families. Cancer Epidemiol Biomarkers Prev 14:1666-1671.
51. Weitzel JN, Lagos VI, Herzog JS, Judkins T, Hendrickson B, Ho JS, Ricker CN, Lowstuter KJ, Blazer KR, Timlinson G, et al. (2007) Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 16:1615-1620.
52. Weitzel JN, Blazer KR, Macdonald DJ, Culvert JO and Offit K (2013) Genetics, genomics, and cancer risk assessment: State of the art and future directions in the era of personalized medicine. CA Cancer J Clin [Epub ahead of print].
53. Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, Jungbluth C, Cina C, Duncan P, Unzeitig G, et al. (2013) Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: A report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol 31:210-216.
54. International Agency for Research on Cancer (IARC) http://p53.iarc.fr/TP53GeneVariations.aspx